Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06081959 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants planned, started 2023-10-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264, Eribulin, Capecitabine, Gemcitabine and Vinorelbine.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Sichuan Kelun-Biotech, Capecitabine and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Shares Sichuan Kelun-Biotech, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.